Full Breakdown
New Treatment for Sleeping Sickness Approved by European Regulators
2/27/2026, 9:48:21 PM
Overview of the New Treatment
European drug regulators have endorsed acoziborole, a new treatment for sleeping sickness developed by Sanofi and the Drugs for Neglected Diseases initiative (DNDi). This decision by the European Medicines Agency is considered a significant advancement in the fight against sleeping sickness, particularly in the Democratic Republic of the Congo, which has the highest incidence of the disease. Acoziborole offers a simpler treatment regimen, requiring only three pills taken as a one-time dose, compared to existing therapies that necessitate lengthy hospital visits and painful procedures.
Background on Sleeping Sickness
Sleeping sickness, caused by parasites transmitted through tsetse fly bites, primarily affects rural populations in sub-Saharan Africa. The disease can lead to severe neurological symptoms and, if untreated, can result in coma and death. Historically, treatments have been limited and often toxic, contributing to the disease's persistence in impoverished regions. The World Health Organization aims to halt the spread of the most common form of sleeping sickness by 2030, following a significant decline in reported cases from over 10,000 in 2009 to fewer than 600 in 2024.
Impact of Acoziborole
The approval of acoziborole is expected to enhance treatment accessibility, particularly for those living in remote areas with limited healthcare access. A pivotal study involving approximately 200 patients in Congo and Guinea demonstrated that over 95% of those treated with acoziborole were considered cured 18 months later. This new treatment eliminates the need for spinal taps, which were previously required to assess the infection stage and determine appropriate therapies.
Official Statements & Responses
Dr. Junior Matangila from the Drugs for Neglected Diseases initiative emphasized the potential of acoziborole to accelerate the elimination of sleeping sickness, stating, “This disease is on the brink of elimination.” Sanofi officials noted that if successful, this could mark the first time an infectious disease is eradicated without a vaccine. Additionally, Sanofi has committed to donating doses to the World Health Organization, ensuring that the treatment will be free for patients.
Criticism & Opposition
Despite the optimism surrounding acoziborole, some experts, including Monica Mugnier from Johns Hopkins University, caution that the approval does not resolve all challenges. She highlighted uncertainties regarding the locations of the disease-causing parasites and the need for ongoing surveillance and research.
Conflicting Reports & Gaps
While the approval of acoziborole is a positive development, there remains a lack of comprehensive data on the total number of undiagnosed cases of sleeping sickness, which complicates efforts to assess the full impact of the new treatment.
Conclusion
The endorsement of acoziborole represents a pivotal moment in the fight against sleeping sickness, potentially transforming treatment protocols and improving patient outcomes in affected regions. However, ongoing challenges and uncertainties must be addressed to ensure the disease's elimination.
